Search results
Showing 1 to 7 of 7 results for estradiol and estradiol/norethisterone acetate
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]
In development [GID-TA10873] Expected publication date: 16 April 2025
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.
This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.
September 2000 TA032 Multiple sclerosis - beta interferon and glatiramer acetate 26 November 2001 TA218 Myelodysplastic syndrome -...
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.